Register
Forgot your password?

Antithrombotic therapy and hemorrhagic complications in the perioperative period in patients with chronic limb threatening ischemia

Authors: Maksimkin D. A., Khalabuzar V. A., Faybushevich A. G., Gitelzon E. A.

Company: Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Original articles


DOI: https://doi.org/10.24022/1997-3187-2024-18-2-214-224

For citation: Maksimkin D.A., Khalabuzar V.A., Faybushevich A.G., Gitelzon E.A. Antithrombotic therapy and hemorrhagic complications in the perioperative period in patients with chronic limb threatening ischemia. Creative Cardiology. 2024; 18 (2): 214–224 (in Russ.). DOI: 10.24022/1997-3187-2024-18-2-214-224

Received / Accepted:  23.01.2024 / 16.04.2024

Keywords: anticoagulant therapy antithrombotic therapy hemorrhagic complications chronic limb threatening ischemia bleeding



Subscribe 🔒

 

Abstract

Objective. To evaluate the effect of various antithrombotic treatment regimens on the incidence of hemorrhagic complications that occur in the perioperative period in patients with chronic limb threatening ischemia.

Material and methods. At the first stage, the medical histories and outpatient records of 766 patients with chronic limb threatening ischemia (from 2006 to 2020) were retrospectively analyzed in order to identify hemorrhagic complications and the antithrombotic therapy used. At the II – main stage, 114 patients were operated on from 2021 to 2023 who had one or more risk factors for major bleeding. Observation periods: hospital.

Results. In the structure of bleeding at the first stage of the study, the most significant cohort of patients with hemorrhagic complications were taking acetylsalicylic acid in combination with warfarin (OR 1.14, 95% CI 0.394–3.298, р = 0.012), acetylsalicylic acid in combination with clopidogrel (OR 1.75, 95% CI 1.112–3.360, р = 0.014) and triple antithrombotic therapy (OR 20.22, 95% CI 6.202–65.921, р = 0.001). At stage II of the study, hemorrhagic complications were observed significantly often in patients taking triple antithrombotic therapy (OR 4.82, 95% CI 2.124–10.613, р = 0.003).

Conclusion. The hemorrhagic complications that occur in the perioperative period during the use of various antithrombotic therapy regimens are observed in 4–5% of patients with CLTI. Analyzing the presented study, it should be noted that most often combinations of acetylsalicylic acid with warfarin, dual antiplatelet therapy as well as triple antithrombotic therapy, are associated with hemorrhagic complications. The proposed measures to prevent bleeding can reliably reduce the incidence of its development and associated complications.

References

  1. Gurbel P., Fox K., Tantry U., Cate H., Weitz J. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation. 2019; 139 (18): 2170–2185. DOI:10.1186/1472-6963-11-135
  2. Gottsäter A. Antithrombotic treatment in lower extremity peripheral arterial disease. Front. Cardiovasc. Med. 2021; 8: 773214. DOI:10.3389/fcvm.2021.773214
  3. Bhardwaj B., Spertus J., Kennedy K., Schuyler W., Safley D., Tsai T. et al. Bleeding complications in lower-extremity peripheral vascular interventions insights from the NCDR PVI Registry. JACC Cardiovasc. Interv. 2019; 12 (12): 1140–1149. DOI: 10.1016/j.jcin.2019.03.012
  4. Twine C., Kakkos S., Aboyans V., Baumgartner I., Behrendt C., Bellmunt-Montoya S. et al. Editor’s choice – European Society for Vascular Surgery (ESVS) 2023 Clinical practice Guidelines on antithrombotic therapy for vascular diseases. Eur. J. Vasc. Endovasc. Surg. 2023; 65 (5): 627–689. DOI: 10.1016/j.ejvs.2023.03.042
  5. Barnes G. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology Am. Soc. Hematol. Educ. Program. 2020; 2020 (1): 642–648. DOI: 10.1182/hematology.2020000151.
  6. Wagner J., Lock J, Kastner C., Klein I., Krajinovic K., Löb S. et al. Perioperative management of anticoagulant therapy. Innov. Surg. Sci. 2019; 4 (4): 144–151. DOI: 10.1515/iss-2019-0004
  7. Moster M., Bolliger D. Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update. Current. Anesthesiology Rep. 2022; 12: 286–296. DOI: 10.1007/s40140-021-00511-z
  8. Tang T., Zhang M., Li W., Hu N., Du X., Ran F., Li X. Oral anticoagulant and antiplatelet therapy for peripheral arterial disease: a meta-analysis of randomized controlled trials. Clin. Appl. Thromb. Hemost. 2021; 27: 1076029621996810. DOI: 10.1177/1076029621996810
  9. Pomozi E., Nagy R., Fehérvári P., Hegyi P., Kiss B., Dembrovszky F. et al. Direct oral anticoagulants as the first choice of anticoagulation for patients with peripheral artery disease to prevent adverse vascular events: a systematic review and meta- analysis. J. Cardiovasc. Dev. Dis. 2023; 10 (2): 65. DOI: 10.3390/jcdd10020065
  10. Nagy A., Kim J., Jeong M., Heo M., Putzu A., Belletti A. et al. Non-vitamin K oral anticoagulants for coronary or peripheral artery disease: a systematic review and meta-analysis of mortality and major bleeding. Minerva Cardioangiol. 2019; 67 (6): 477–486. DOI: 10.23736/S0026-4725.19.05043-6
  11. Lv M., Jiang S., Wu T., Chen W., Zhang J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants combined with antiplatelet drugs for patients with peripheral artery disease: A systematic review and meta-analysis of randomized controlled trials. Vascular. 2022; 30 (1): 97–104. DOI: 10.1177/17085381211003694
  12. Aday A., Antonio Jutierrez J. Antiplatelet therapy following peripheral arterial interventions: the choice is yours. Circ. Cardiovasc. Interv. 2020; 13 (8): e009727. DOI: 10.1161/CIRCINTERVENTIONS.120.009727 Tsai S., Li Y., Lee C., Cha S., Wang Y., Su T. et al. Mono or dual antiplatelet therapy for treating patients with peripheral artery disease after lower extremity revascularization: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2022; 15 (5): 596. DOI: 10.3390/ph15050596
  13. Bonaca M., Bauersachs R., Anand S., Debus S., Nehler M., Patel M. et al. Rivaroxaban in peripheral artery disease after revascularization. N. Engl. J. Med. 2020; 382 (21): 1994–2004. DOI: 10.1056/NEJMoa2000052
  14. Hiatt W., Bonaca M., Patel M., Nehler M., Debus S., Anand S. et al. Rivaroxaban and Aspirin in peripheral artery disease lower extremity revascularization. Impact of concomitant Clopidogrel on efficacy and safety. Circulation. 2020; 142 (23): 2219–2230. DOI: 10.1161/CIRCULATIONAHA.120.050465
  15. Franco L., Becattini C., Beyer-Westendorf J., Vanni S., Nitti C., Re R. et al. Definition of major bleeding: prognostic classification. J. Thromb. Haemost. 2020; 18 (11): 2852–2860. DOI:10.1111/jth.15048
  16. Almasri J., Adusumalli J., Asi N., Lakis S, Alsawas M., Prokop L. et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. J. Vasc. Surg. 2018; 68 (2): 624–633. DOI:10.1016/j.jvs.2018.01.066
  17. Ciocan R., Bolboacă S., Rădulescu S., Stancu B., Ciocan A., Gherman C. Demographic and comorbidity pattern of patients with critical limb ischemia. Folia Med. (Plovdiv). 2017; 59 (1): 14–22. DOI:10.1515/folmed-2017-0014
  18. Iida O., Takahara M., Soga Y., Kodama A., Terashi H., Azuma N. Three-year outcomes of surgical versus endovascular revascularization for critical limb ischemia the SPINACH study (surgical reconstruction versus peripheral intervention in patients with critical limb ischemia). Circ. Cardiovasc. Interv. 2017; 10 (12): e005531. DOI: 10.1161/CIRCINTERVENTIONS.117.005531
  19. Narula N., Dannenberg A., Olin J., Bhatt D., Johnson K., Nadkarni G. et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J. Am. Coll. Cardiol. 2018; 72 (18): 2152–2163. DOI: 10.1016/j.jacc.2018.08.002
  20. Komarov A.L., Novikova E.S., Guskova E.V., Yarovaya E.B., Samko A.N., Panchenko E.P. New possibilities of antithrombotic therapy of patients with peripheral and widespread atherosclerotic lesion. Rational Pharmacotherapy in Cardiology. 2018; 14 (2): 272–283 (in Russ). DOI: 10.20996/1819-6446-2018-14-2-272-283
  21. Espinola-Klein C., Weißer G., Schmitt V., Schwaderlapp M., Munzel T. Antithrombotic therapy in peripheral arterial disease. Front. Cardiovasc. Med. 2022; 9: 927645. DOI: 10.3389/fcvm.2022.927645
  22. Anand S., Yusuf S., Xie C., Pogue J., Eikelboom J., Budaj A. et al. Warfarin antiplatelet vascular evaluation trial investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N. Engl. J. Med. 2007; 357: 217–227. DOI: 10.1056/NEJMoa065959
  23. Bakhru M., Bhatt D. Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleve Clin. J. Med. 2008; 75 (4): 289–295. DOI: 18491435. 10.3949/ccjm.75.4.289 Elbadawi A., Barssoum K., Megaly M., Rai D., Elsherbeeny A., Mansoor H. et al. Sex differences in trends and in-hospital outcomes among patients with critical limb ischemia: a Nationwide Analysis. J. Am. Heart Assoc. 2021; 10 (18): e022043. DOI: 10.1161/JAHA.121.022043

About Authors

  • Daniil A. Maksimkin, Cand. Med. Sci., Associate Professor; ORCID
  • Vladislav A. Khalabuzar, Postgraduate; ORCID
  • Aleksandr G. Faybushevich, Cand. Med. Sci., Associate Professor, Chief of Chair of Hospital Surgery and Pediatric Surgery; ORCID
  • Ekaterina A. Gitelzon, Cand. Med. Sci., Assistant Professor; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by